Группа авторов

Individual Participant Data Meta-Analysis


Скачать книгу

(although see Section 3.12 regarding prospective IPD meta‐analysis).

       The IPD obtained and used will not contain any direct identifiers for participants, such as names or identifying numbers that are known to anyone outside of the immediate trial management team.

       The IPD will be held securely at the central research team’s host institution with access restricted to members of the team.

       The IPD will be held, managed and used according to a binding data‐sharing agreement or contract, including commitment that the recipient project team will make no attempt to re‐identify trial participants.

       The research questions to be addressed in the IPD meta‐analysis project are the same as or close to those to which the trial participants originally consented.

      It is also worth highlighting these points in the IPD meta‐analysis protocol, and in data‐sharing agreements, as they may help IPD providers gain permission to release their data.

      Discussions around ethical approval might draw on evidence that patients are generally supportive of their clinical trial data being re‐used in further research activity provided that there are appropriate safeguards around confidentiality. A consultation exercise undertaken in 2008 by the National Cancer Research Institute (NCRI) demonstrated that most respondents believed that material and data collected from patients with cancer should be used, without identifiable information, as broadly as possible and that retrospectively seeking consent was inappropriate.82 A systematic review of quantitative and qualitative research studies found widespread, although conditional, support among patients and the public for data sharing for health research.83 Although participants recognised actual or potential benefits, they expressed concerns about breaches of confidentiality and potential abuses of the data.

      Source: Adapted from Phillips et al.,85 with permission from BMJ Publishing Group Ltd.

Country Study type(s) Review body approached Review body Answer
Belgium Prospective Yes University Hospital Review Boards Agreed
Bulgaria Prospective
Canada Prospective No1
Canada Institutional Review Board Agreed
Chile Prospective No1
Germany Prospective No1
Italy Prospective No1
Netherlands Prospective No1
Slovenia Prospective Medical Ethics Committee Agreed
Switzerland Prospective and retrospective Hospital Review Board Agreed
Turkey Audit
UK Audit NHS Ethics Committee Agreed
United States Retrospective notes review Institutional Review Board Agreed
United States Prospective No1